parsabiv

parsabiv Uses, Dosage, Side Effects, Food Interaction and all others data.

parsabiv is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. parsabiv was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.

Following a single intravenous bolus administration of etelcalcetide, PTH levels decreased within 30 minutes post dose. In the single-dose study, the extent and duration of the reduction in PTH increased with increasing dose. Reduction in PTH levels correlated with plasma etelcalcetide concentrations in hemodialysis patients. The reduction in PTH resulted in reductions in calcium and attenuation of post-dialytic phosphate elevation. The effect of reducing PTH levels was maintained throughout the 6-month dosing period when etelcalcetide was administered by intravenous bolus three times a week.

Trade Name parsabiv
Availability Prescription only
Generic Etelcalcetide
Etelcalcetide Other Names Etelcalcetida, Etelcalcetide, ételcalcétide, Etelcalcetidum, Velcalcetide
Related Drugs Rayaldee, Parsabiv, calcifediol
Weight 10mg, 2.5mg, 5mg, , 5mg/ml
Type Solution For Injection, Intravenous Solution
Formula C38H73N21O10S2
Weight Average: 1048.26
Monoisotopic: 1047.529069983
Protein binding

Etelcalcetide is predominately bound to plasma albumin by reversible covalent binding. Non-covalent binding of etelcalcetide to plasma proteins is low with a fraction unbound ratio of 0.53. The ratio of blood-to-plasma [14C]-etelcalcetide concentrations is approximately 0.6.

Groups Approved, Investigational
Therapeutic Class
Manufacturer Amgen Europe B,v,, Amgen Ltd
Available Country Saudi Arabia, United Kingdom, United States,
Last Updated: September 19, 2023 at 7:00 am
parsabiv
parsabiv

Uses

parsabiv is a calcium sensing receptor agonist used to treat secondary hyperparathyroidism in patients with chronic kidney disease who require hemodialysis.

parsabiv is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

parsabiv is also used to associated treatment for these conditions: Secondary Hyperparathyroidism (SHPT)

How parsabiv works

parsabiv is a calcimimetic agent that allosterically modulates the calcium-sensing receptor (CaSR). parsabiv binds to the CaSR and enhances activation of the receptor by extracellular calcium. Activation of the CaSR on parathyroid chief cells decreases PTH secretion.

Food Interaction

No interactions found.

parsabiv Disease Interaction

Moderate: arrhythmia, GI bleeding, heart failure, seizures

Volume of Distribution

796 L

Elimination Route

The pharmacokinetics of etelcalcetide is linear and does not change over time following single (5 to 60 mg) and multiple intravenous doses (2.5 to 20 mg) in chronic kidney disease patients with secondary hyperparathyroidism requiring hemodialysis. parsabiv exhibited tri-exponential decay following intravenous administration. Based on population pharmacokinetic analysis, following three times a week intravenous dosing at the end of each 3- to 6-hour hemodialysis session in chronic kidney disease patients, etelcalcetide plasma levels reached steady state in 7-8 weeks after dosing with a predicted accumulation ratio of 3- to 4-fold

Half Life

3 to 4 days

Clearance

7.66 L/hr

Elimination Route

parsabiv is cleared by renal excretion

Innovators Monograph

You find simplified version here parsabiv

*** Taking medicines without doctor's advice can cause long-term problems.
Share